title: Periorbital dermatitis as a side effect of topical dorzolamide.
abstract: OBJECTIVE
  To report periorbital dermatitis as a late side effect of topical dorzolamide hydrochloride (Trusopt), a drug used to reduce intraocular pressure.
  
  
  METHODS
  A retrospective study of 14 patients who developed periorbital dermatitis while using topical dorzolamide hydrochloride was undertaken. Six patients underwent patch testing for sensitivity to Trusopt, dorzolamide hydrochloride, and the preservative benzalkonium chloride.
  
  
  RESULTS
  The periorbital dermatitis occurred after a mean period of 20.4 weeks of commencing dorzolamide hydrochloride therapy. 13 patients had used preserved topical beta blocker treatment for a mean period of 34.2 months without complication before the introduction of dorzolamide. In eight (57.1%) the dermatitis resolved completely after discontinuing dorzolamide but in six (42.9%) resolution of the dermatitis did not occur until the concomitant preserved beta blocker was stopped and substituted with preservative free drops. Patch testing for sensitivity to Trusopt, dorzolamide hydrochloride, and benzalkonium chloride was negative.
  
  
  CONCLUSIONS
  These findings suggest that dorzolamide can cause severe periorbital dermatitis. Although the dermatitis may resolve when dorzolamide is discontinued, this does not always occur and in some patients all topical medication containing benzalkonium chloride needs to be stopped.
authors.affiliation: Department of Ophthalmology, John Radcliffe Hospitals NHS Trust, Oxford, OX2 6HE, UK.
authors.forename: Y M
authors.initials: YM
authors.lastname: Delaney
authors.forename: J F
authors.initials: JF
authors.lastname: Salmon
authors.forename: F
authors.initials: F
authors.lastname: Mossa
authors.forename: B
authors.initials: B
authors.lastname: Gee
authors.forename: K
authors.initials: K
authors.lastname: Beehne
authors.forename: S
authors.initials: S
authors.lastname: Powell
mesh_terms: D000287:Administration, Topical; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000368:Aged; D000369:Aged, 80 and over; D000959:Antihypertensive Agents / Q000009:adverse effects*; D003875:Drug Eruptions / Q000209:etiology*; D005148:Facial Dermatoses / Q000139:chemically induced*; D005260:Female; D005901:Glaucoma / Q000188:drug therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D013449:Sulfonamides / Q000008:administration & dosage / Q000009:adverse effects*; D013876:Thiophenes / Q000008:administration & dosage / Q000009:adverse effects*
chemical_list: D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D013449:Sulfonamides; D013876:Thiophenes; C062765:dorzolamide